BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 26840268)

  • 1. Development of a metabolites risk score for one-year mortality risk prediction in pancreatic adenocarcinoma patients.
    Fontana A; Copetti M; Di Gangi IM; Mazza T; Tavano F; Gioffreda D; Mattivi F; Andriulli A; Vrhovsek U; Pazienza V
    Oncotarget; 2016 Feb; 7(8):8968-78. PubMed ID: 26840268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolomic profile in pancreatic cancer patients: a consensus-based approach to identify highly discriminating metabolites.
    Di Gangi IM; Mazza T; Fontana A; Copetti M; Fusilli C; Ippolito A; Mattivi F; Latiano A; Andriulli A; Vrhovsek U; Pazienza V
    Oncotarget; 2016 Feb; 7(5):5815-29. PubMed ID: 26735340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prediction of prognosis of patients with pancreatic adenocarcinoma with curative intent resection by means of histologic grade and pathologic N stage].
    Soriano-Izquierdo A; Adet AC; Gallego R; Miquel R; Castells A; Pellisé M; Nadal C; López-Boado MA; Piqué JM; Gascón P; Conill C; Bombí A; Fernández-Cruz L; Maurel J; Navarro S
    Med Clin (Barc); 2009 Feb; 132(5):163-71. PubMed ID: 19211081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting early mortality in resectable pancreatic adenocarcinoma: A cohort study.
    Sohal DP; Shrotriya S; Glass KT; Pelley RJ; McNamara MJ; Estfan B; Shapiro M; Wey J; Chalikonda S; Morris-Stiff G; Walsh RM; Khorana AA
    Cancer; 2015 Jun; 121(11):1779-84. PubMed ID: 25676016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated serum CA72-4 levels predict poor prognosis in pancreatic adenocarcinoma after intensity-modulated radiation therapy.
    Liu P; Zhu Y; Liu L
    Oncotarget; 2015 Apr; 6(11):9592-9. PubMed ID: 25860937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolite Profiles of the Serum of Patients with Non-Small Cell Carcinoma.
    Mazzone PJ; Wang XF; Beukemann M; Zhang Q; Seeley M; Mohney R; Holt T; Pappan KL
    J Thorac Oncol; 2016 Jan; 11(1):72-8. PubMed ID: 26762741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CEA and CA-19.9 serum tumor markers as prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis.
    Tsavaris N; Kosmas C; Papadoniou N; Kopterides P; Tsigritis K; Dokou A; Sarantonis J; Skopelitis H; Tzivras M; Gennatas K; Polyzos A; Papastratis G; Karatzas G; Papalambros A
    J Chemother; 2009 Dec; 21(6):673-80. PubMed ID: 20071292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperfibrinogen Is Associated With the Systemic Inflammatory Response and Predicts Poor Prognosis in Advanced Pancreatic Cancer.
    Qi Q; Geng Y; Sun M; Chen H; Wang P; Chen Z
    Pancreas; 2015 Aug; 44(6):977-82. PubMed ID: 25931258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Serum Markers of Esophageal Adenocarcinoma by Global and Targeted Metabolic Profiling.
    Sanchez-Espiridion B; Liang D; Ajani JA; Liang S; Ye Y; Hildebrandt MA; Gu J; Wu X
    Clin Gastroenterol Hepatol; 2015 Oct; 13(10):1730-1737.e9. PubMed ID: 25998788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors.
    Cleary SP; Gryfe R; Guindi M; Greig P; Smith L; Mackenzie R; Strasberg S; Hanna S; Taylor B; Langer B; Gallinger S
    J Am Coll Surg; 2004 May; 198(5):722-31. PubMed ID: 15110805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible?
    Schnelldorfer T; Ware AL; Sarr MG; Smyrk TC; Zhang L; Qin R; Gullerud RE; Donohue JH; Nagorney DM; Farnell MB
    Ann Surg; 2008 Mar; 247(3):456-62. PubMed ID: 18376190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct serum metabolomics profiles associated with malignant progression in the KrasG12D mouse model of pancreatic ductal adenocarcinoma.
    LaConti JJ; Laiakis EC; Mays AD; Peran I; Kim SE; Shay JW; Riegel AT; Fornace AJ; Wellstein A
    BMC Genomics; 2015; 16 Suppl 1(Suppl 1):S1. PubMed ID: 25923219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential prognostic significance of a new proteomic profile in patients with advanced pancreatic adenocarcinoma.
    Kobayashi S; Ueno M; Irie K; Goda Y; Aoyama T; Morinaga S; Ohkawa S; Morimoto M
    Pancreatology; 2015; 15(5):525-530. PubMed ID: 26255025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. D-mannose: a novel prognostic biomarker for patients with esophageal adenocarcinoma.
    Gu J; Liang D; Pierzynski JA; Zheng L; Ye Y; Zhang J; Ajani JA; Wu X
    Carcinogenesis; 2017 Feb; 38(2):162-167. PubMed ID: 28062409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatic ductal adenocarcinoma is associated with a distinct urinary metabolomic signature.
    Davis VW; Schiller DE; Eurich D; Bathe OF; Sawyer MB
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S415-23. PubMed ID: 23096698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
    Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
    Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and pathological features of five-year survivors after pancreatectomy for pancreatic adenocarcinoma.
    Kimura K; Amano R; Nakata B; Yamazoe S; Hirata K; Murata A; Miura K; Nishio K; Hirakawa T; Ohira M; Hirakawa K
    World J Surg Oncol; 2014 Nov; 12():360. PubMed ID: 25429841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolomics identified new biomarkers for the precise diagnosis of pancreatic cancer and associated tissue metastasis.
    Luo X; Liu J; Wang H; Lu H
    Pharmacol Res; 2020 Jun; 156():104805. PubMed ID: 32278036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations of Socioeconomic Variables With Resection, Stage, and Survival in Patients With Early-Stage Pancreatic Cancer.
    Shapiro M; Chen Q; Huang Q; Boosalis VA; Yoon CH; Saund MS; Whang EE; Gold JS
    JAMA Surg; 2016 Apr; 151(4):338-45. PubMed ID: 26581025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatic adenocarcinoma with venous involvement: is up-front synchronous portal-superior mesenteric vein resection still justified? A survey of the Association Française de Chirurgie.
    Delpero JR; Boher JM; Sauvanet A; Le Treut YP; Sa-Cunha A; Mabrut JY; Chiche L; Turrini O; Bachellier P; Paye F
    Ann Surg Oncol; 2015; 22(6):1874-83. PubMed ID: 25665947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.